EDAP TMS SA reported the first quarter of 2026 results: revenue $17.8 million, net income $9.1 million, or ($0.24) per share, EPS ($0.24) per share. Guidance reaffirmed.
“focus on the high-growth, high margin opportunity in focal therapy through its Focal One Robotic HIFU platform. Company Total worldwide revenue for the first quarter of 2026 was $17.8 million, compared to $14.3 million for the same period in 2025. Gross profit margin on net sales was 45.7%, up from 42.0% for the same period in 2025. The margin improvement was”
Debt Financings
EDAP TMS SA incurred credit facility of €12.0 million with European Investment Bank maturing five years from the disbursement date.
“the Company has satisfied the conditions to draw €12.0 million in the second tranche of the term loan facility (“Tranche B”). The Tranche B borrowings were requested on April 1, 2026 and are expected to be disbursed by EIB in late April 2026.”
Earnings Releases
EDAP TMS SA updated its the fourth quarter and full-year 2025 guidance (reaffirmed).
“On March 25, 2026, EDAP TMS S.A. issued a press release and will hold a conference call regarding its financial results for the quarter ended December 31, 2025.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.